Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2021

Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

Published 9 April 2021
Categorized as -others, 2021, Invir.IO, Publication, TG6002

Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 – TG6002 AACR EN

Published 9 April 2021
Categorized as -others, 2021, Press release, TG6002

Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021

20210407 document AG EN

Published 7 April 2021
Categorized as 2021, Press release

Availability of Transgene’s 2020 Universal Registration Document

20210401 Transgene mise a disposition ddr 2020 EN

Published 1 April 2021
Categorized as 2021, Press release

Immunocompetent cancer-on-chip models to assess immuno-oncology therapy

Tengku Ibrahim Maulana, et al. Adv Drug Deliv Rev., March 30 2021 – Read the article Publication

Published 30 March 2021
Categorized as -others, 2021, Publication

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

20210310 Transgene TG4001 randomized Phase II EN

Published 10 March 2021
Categorized as 2021, Press release, TG4001, TG4001

Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022

20210310 Transgene Results 2020 EN

Published 10 March 2021
Categorized as 2021, Press release

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 – Transgene Scientific Conferences

Published 2 March 2021
Categorized as 2021, Invir.IO, Myvac, Press release

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 – Transgene BT-001 FPI – EN

Published 1 March 2021
Categorized as 2021, BT-001, Invir.IO, Press release

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Jérémy Béguin, et al. Sci Rep., January 26 2021 – Read the article Publication

Published 26 January 2021
Categorized as -others, 2021, Publication, TG6002

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu